News on research and diagnostic developments in neuroscience.
The researchers have built a benchtop breath test currently being validated, but a commercial test could be more than a decade away.
A spin-out of the University of Geneva and Barcelona's Vall d’Hebron Research Institute, the company is focused on protein biomarkers for brain injury.
The study showed the test had a high negative predictive value, but critics cited a lack of data on cost and outcomes.
The Elecsys beta-Amyloid (1-42) CSF and Elecsys Phospho-Tau (181P) CSF assays are used to measure peptide biomarkers in the CSF of patients with cognitive impairment.
With funding from Bill Gates and others, the Diagnostics Accelerator aims to support the development of new biomarkers for the early detection of Alzheimer's.